4.7 Article

Anti-GPVI-associated ITP:: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ-chain complex from the human platelet surface

Journal

BLOOD
Volume 104, Issue 5, Pages 1350-1355

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2004-03-0896

Keywords

-

Categories

Funding

  1. NHLBI NIH HHS [HL 44612, HL 067311] Funding Source: Medline

Ask authors/readers for more resources

Platelet glycoprotein (GP) VI is a 62-kDa membrane glycoprotein that exists on both human and murine platelets in a noncovalent complex with the Fc receptor (FcR) gamma chain. The GPVI/FcRgamma-chain complex serves as the major activating receptor for Collagen, as evidenced by observations that platelets genetically deficient in GPVI or the FCRgamma Chain are highly refractory to collagen-induced platelet activation. Recently, several different rat anti-murine GPVI monoclonal antibodies, termed JAQs 1, 2, and 3, were produced that had the unique property of immunodepleting GPVI from the murine platelet surface and rendering it unresponsive to Collagen or GPVI-specific agonists like convuixin or collagen-related peptide (CRP). Herein, we describe a patient with a mild bleeding disorder and a moderately reduced platelet count whose platelets fail to become activated in response to Collagen or CRP and inefficiently adhere to and form thrombi on immobilized Collagen under conditions of arterial shear. Although the amount of GPVI platelet mRNA and the nucleotide sequence of the GPVI gene were found to be normal, both GPVI and the FcRgamma chain were nearly absent from the platelet surface and were markedly reduced in whole-platelet detergent lysates. Patient plasma contained an autoantibody that bound specifically to GPVI-positive, normal platelets, and cleared soluble GPVI from the plasma, suggesting that the patient suffers from a rare form of idiopathic thrombocytopenic purpura caused by a GPVI-specific autoantibody that mediates clearance of the GPVI/FCRgamma-chain complex from the platelet surface. Since antibody-induced GPVI shedding now has been demonstrated in both, humans and mice, these studies may provide a rationale for developing therapeutic reagents that induce temporary depletion of GPVI for the treatment of clinical thrombosis. (C) 2004 by The American Society of Hematology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available